$TFX

Teleflex Inc. completed enrollment of 102 patients in the BIOMAG™-LL Clinical Study across 14 European centers to evaluate 35 mm and 40 mm Freesolve™ Resorbable Magnesium Scaffolds for long coronary lesions. The study aims to assess safety and effectiveness, with primary endpoint Target Lesion Failure (TLF) rate at 12 months. The data could expand treatment options for diffuse coronary artery disease, supporting the broader use of resorbable scaffold technology.

Teleflex (TFX) reported that a study in the American Journal of Infection Control found its Arrowg+ard Technology catheters reduced central line infections by 70% in ICU patients. This data may influence hospital purchasing decisions and support Teleflex's investment narrative, which focuses on higher margins and profitability. However, near-term challenges include integration issues and meeting cost-saving targets.

RBC Capital reaffirmed a Buy rating on Teleflex (TFX) with a $155 target. Shares closed at $126.11. Analyst consensus is Moderate Buy with $157.67 avg target. Q2 revenue was $570.33M, down from $780.89M YoY.

Argus raised its target price for Teleflex Incorporated (TFX) to $133.00. The company, based in Wayne, Pennsylvania, manufactures hospital supplies and medical devices. No other details were provided.

PacBio (PACB) rose 5.8% after a $27.1M contract with the U.S. Department of Veterans Affairs. Nvidia (NVDA) gained 2.7% following a $150B share buyback authorization. Palo Alto Networks (PANW) increased 5.1% after BTIG raised its price target to $425. Teleflex (TFX) climbed 4.5% following a BofA Securities upgrade.

Teleflex (TFX) stock rose 4.6% after BofA upgraded it to Buy, raising its price target to $158. The bank cited improved execution risks and potential EPS upside. Zacks Research also upgraded the stock to Strong-Buy. The company's recent earnings beat expectations. The S&P 500, Dow Jones, and Nasdaq all declined, highlighting the company-specific nature of the rally.

U.S. stocks declined Monday as oil prices surged and Treasury yields climbed after Trump rejected Iran's Hormuz proposal. WTI crude rose 4.2% to $96.31, Brent 4.0% to $108.50. The 10-year yield hit 5.27%. Nasdaq 100 fell 1.3%, S&P 500 0.8%. MongoDB (MDB) dropped 18.5% after CEO resignation. Nu Holdings (NU) fell 8.8% amid Monzo acquisition talks.

Analysts upgraded several companies: Deutsche Bank raised Royal Caribbean (RCL) to Buy with a $299 target, Raymond James upgraded Park Hotels (PK) to Strong Buy with a $19 target, Keybanc upgraded First Solar (FSLR) to Sector Weight, B of A upgraded Teleflex (TFX) to Buy with a $158 target, and Rothschild upgraded CF Industries (CF) to Neutral with a $110 target.

JPMorgan reiterates Apple as overweight, citing healthy iPhone lead times. KeyBanc upgrades First Solar to sector weight. Raymond James upgrades Park Hotels to strong buy. JPMorgan lowers Tesla's price target to $415. Jones Trading initiates CoreWeave as buy. Jefferies downgrades Roblox to underperform. Deutsche Bank upgrades Royal Caribbean to buy. Wells Fargo upgrades Sweetgreen to overweight. Baird raises Micron's price target to $1,520. Bank of America initiates IonQ as buy.

Wall Street analysts issued updates on several companies. First Solar (FSLR) was upgraded to Sector Weight at KeyBanc. Liberty Energy (LBRT) was upgraded to Overweight with a $27 target at Barclays. PepsiCo (PEP) was downgraded to Hold with a $138 target at Deutsche Bank. Roblox (RBLX) was downgraded to Underperform with a $38 target at Jefferies.